Durability of Dolutegravir-Based Regimens: A 5-Year Prospective Observational StudyLucia Taramasso, Chiara Bellacosa, Gioacchino Angarano et al.|AIDS Patient Care and STDs|2021Cited by 25
Growing old with antiretroviral therapy or elderly people in antiretroviral therapy: two different profiles of comorbidity?Paolo Maggi, Paolo Bonfanti, Giuseppe Vittorio De Socio et al.|BMC Infectious Diseases|2022Cited by 18
Lipids and Transaminase in Antiretroviral-Treatment-Experienced People Living with HIV, Switching to a Doravirine-Based vs. a Rilpivirine-Based Regimen: Data from a Real-Life SettingPaolo Maggi, Paolo Bonfanti, Elena Ricci et al.|Viruses|2023Cited by 17
Real-life safety of Emtricitabine/Tenofovir Alafenamide/BictegravirNicola Squillace, Elena Ricci, Paolo Maggi et al.|PLoS ONE|2023Cited by 14
Reversibility of Central Nervous System Adverse Events in Course of ArtLucia Taramasso, Paolo Bonfanti, Giancarlo Orofino et al.|Viruses|2022Cited by 14